An Van den Bergh
Overview
Explore the profile of An Van den Bergh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
483
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Canhao P, Snoeys J, Geerinckx S, van Heerden M, Van den Bergh A, Holm C, et al.
Eur J Pharm Sci
. 2025 Jan;
107025.
PMID: 39864598
The purpose of this study was to evaluate EpiColon, a novel human organotypic 3D colon microtissue prototype, developed to assess colonic drug disposition, with a particular focus on permeability ranking,...
2.
Van Rompaey D, Ray Chaudhuri S, Ahmad M, Cisar J, Van den Bergh A, Ash J, et al.
J Med Chem
. 2024 Dec;
67(24):22282-22290.
PMID: 39666573
Human dose prediction (HDP) is a useful tool for compound optimization in preclinical drug discovery. We describe here our exclusively in silico HDP strategy to triage compound designs for synthesis...
3.
Van Rompaey D, Morrison D, Van den Bergh A, Kurt Wegner J
Mol Pharm
. 2023 Mar;
20(5):2436-2442.
PMID: 37000176
It is common practice in the early drug discovery process to conduct in vitro screening experiments using liver microsomes in order to obtain an initial assessment of test compound metabolic...
4.
Rombouts F, Kusakabe K, Alexander R, Austin N, Borghys H, De Cleyn M, et al.
J Med Chem
. 2021 Sep;
64(19):14175-14191.
PMID: 34553934
The discovery of a novel 2-aminotetrahydropyridine class of BACE1 inhibitors is described. Their pK and lipophilicity were modulated by a pending sulfonyl group, while good permeability and brain penetration were...
5.
Van den Bergh A, Snoeys J, de Zwart L, Ward P, Lopez-Gitlitz A, Ouellet D, et al.
Clin Pharmacokinet
. 2020 Apr;
59(9):1149-1160.
PMID: 32338346
Background: Apalutamide is predominantly metabolized via cytochrome P450 (CYP) 2C8 and CYP3A4, whose contributions change due to autoinduction with repeated dosing. Objectives: We aimed to predict CYP3A4 and CYP2C8 inhibitor/inducer...
6.
Anan K, Iso Y, Oguma T, Nakahara K, Suzuki S, Yamamoto T, et al.
ChemMedChem
. 2019 Oct;
14(22):1894-1910.
PMID: 31657130
The β-site amyloid precursor protein cleaving enzyme 1 (BACE1, also known as β-secretase) is a promising target for the treatment of Alzheimer's disease. A pK lowering approach over the initial...
7.
Tadano G, Komano K, Yoshida S, Suzuki S, Nakahara K, Fuchino K, et al.
J Med Chem
. 2019 Sep;
62(20):9331-9337.
PMID: 31549838
Genetic evidence points to deposition of amyloid-β (Aβ) as a causal factor for Alzheimer's disease. Aβ generation is initiated when β-secretase (BACE1) cleaves the amyloid precursor protein. Starting with an...
8.
Stillhart C, Pepin X, Tistaert C, Good D, Van den Bergh A, Parrott N, et al.
AAPS J
. 2019 Jan;
21(2):19.
PMID: 30673891
The establishment of an in vitro-in vivo correlation (IVIVC) is considered the gold standard to establish in vivo relevance of a dissolution method and to utilize dissolution data in the...
9.
Van den Bergh A, Van Hemelryck S, Bevernage J, Van Peer A, Brewster M, Mackie C, et al.
Mol Pharm
. 2018 May;
15(7):2633-2645.
PMID: 29799758
The aim of the presented retrospective analysis was to verify whether a previously proposed Janssen Biopharmaceutical Classification System (BCS)-like decision tree, based on preclinical bioavailability data of a solution and...
10.
Margolskee A, Darwich A, Pepin X, Pathak S, Bolger M, Aarons L, et al.
Eur J Pharm Sci
. 2016 Sep;
96:598-609.
PMID: 27671970
Predicting oral bioavailability (F) is of importance for estimating systemic exposure of orally administered drugs. Physiologically-based pharmacokinetic (PBPK) modelling and simulation have been applied extensively in biopharmaceutics recently. The Oral...